Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the reduction of clinical signs and mortality associated with K99 E. coli diarrhea in neonatal calves.
Available Presentations: 20 mL vialDownload the product brochure. Download a summary of efficacy data.
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the CFIA for the treatment of bovine infectious disease.
Amplimune is recommended as a one-time immunotherapeutic treatment for the reduction of clinical signs and mortality associated with enterotoxigenic Escherichia coli (ETEC) K99 diarrhea in neonatal calves.
Colibacillosis caused by ETEC K99 is one of the principal causes of neonatal calf diarrhea. ETEC infection occurs most frequently in the first week of life, before the calf can become resistant to the disease.
Early treatment of colibacillosis must be directed toward the control of the bacteria in the intestinal tract. Studies indicate that the optimum times at which to administer Amplimune are:
1. Early in the disease process, and
2. On farms with persistent E. coli scours, treating all calves immediately, one day after birth.
Studies have shown that a single, 1 mL dose of Amplimune can induce an immediate innate immune response in the neonatal calf to minimize and control the damage caused by pathogenic E. coli. Therefore, the calf's ability to overcome the disease challenge is greatly enhanced. As an alternative to antibiotics, Amplimune, with or without fluid therapy, is effective against colibacillosis.
Amplimune is a low volume, single-dose intravenous (IV), sub-cutaneous (SC) and intramuscular (IM) therapy.
For veterinarians to purchase product: